FDA Approves Siemens Mobilett Mira Mobile Digital X-Ray System
Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
The Mobilett Mira’s wireless capacity helps with examinations of patients with limited mobility, and its rotating swivel arm helps increase ease-of-use for clinical staff, the company said.
Similar to their mobile X-ray systems, the device has a rotating swivel arm so that, rather than moving the patient around, radiologists and technologists can move the swivel arm instead. Siemens officials said, though, that theirs is the first mobile X-ray device using a wireless detector, which does away with the data cable needed with other such devices.
The Mobilett Mira has 7-megapixel resolution and exposure times shorter than 1 millisecond.
The X-ray swivel arm moves vertically and rotates 90 degrees, integrating electric connection cables. In addition, the company said, the Mobilett Mira is the first mobile X-ray system that can be maintained and updated via remote monitoring. Siemens Remote Services (SRS) regularly provides the system with recommended software updates.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
